SPRY

ARS Pharmaceuticals, Inc. (SPRY) ESG Analysis Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Environmental

No material ESG-specific environmental disclosures or controversies were provided in the fresh data.

Operationally, the company remains cash-constrained with negative free cash flow, which can limit near-term sustainability investments.

Social

No material ESG-specific social disclosures or controversies were provided in the fresh data.

High stock-based compensation and elevated SG&A intensity suggest continued pressure on employee-cost efficiency, but no new labor or customer issues were reported.

Governance

No material ESG-specific governance disclosures or controversies were provided in the fresh data.

The company continues to show weak profitability and negative cash generation, but the balance sheet remains liquid with a current ratio of 4.94 and no new financing or litigation news was reported.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on ARS Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →